Hannah Granger

Hannah Granger

Auto-generated profile, based on publicly available information

Hannah Granger

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, US

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
ASAlexander E Sullivan
Alexander E Sullivan
HGHannah Granger
Hannah Granger
LDLeonie Dupuis
Leonie Dupuis
JNJonathan Napper
Jonathan Napper
LTLena Tran
Lena Tran
ARAniket S Rali
Aniket S Rali
Introduction: Percutaneous ventricular assist devices (pVADs) are increasingly used in cardiogenic shock but are associated with complications including haemolysis. The aim of this study was to investigate patient characteristics associated with haemolysis in cardiogenic shock patient population. Methods: Consecutive patients were identified using Current Procedural Terminology (CPT) codes for pVAD insertion. Patient characteristics, laboratory and imaging data, and patient outcomes were abstracted manually and using validated automated methods. Laboratory-defined haemolysis required a drop in haemoglobin ≥2 mg/dl with either lactate dehydrogenase ≥250 units/l or undetectable haptoglobin. Clinically significant haemolysis was defined as laboratory-defined haemolysis necessitating transfusion. Primary outcome was the association between haemolysis and on-device and 30-day mortality. Results: A total of 196 patients underwent pVAD insertion for cardiogenic shock during the study period and were included. Laboratory-defined haemolysis occurred in 46 patients (23.5%), of whom 12 (6.1%) had clinically significant haemolysis. Haemolysis occurred more often following emergency insertion, rather than elective insertion (84.8% versus 40.0%, p<0.001) in patients with elevated lactic acid levels (median 2.5 versus 1.6, p=0.016) and elevated heart rates (92.5 BPM versus 86.5 BPM, p=0.023). After multivariable adjustment, there was no association between laboratory-defined haemolysis and on-device (OR 0.6; 95% CI [0.1–3.4]; p=0.565) or 30-day mortality (OR 2.1; 95% CI [0.4–13.0]; p=0.391). Conclusion: Laboratory-defined haemolysis was common in patients with cardiogenic shock and pVAD, but clinically significant haemolysis was not. There was no association between haemolysis and on-device or 30-day mortality.